ClinicalTrials.gg
CompletedNCT03782688P3Updated Mar 23, 2023

Precise Percutaneous Coronary Intervention Plan (P3) Study

An observational study in Stable Coronary Artery Disease, sponsored by Onze Lieve Vrouw Hospital. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Onze Lieve Vrouw Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
127
Ages
18 Years and older
Sex
All
01

Study summary

The PRECISE PERCUTANEOUS CORONARY INTERVENTION (PCI) PLAN STUDY is an investigator-initiated, international and multicenter study of patients with an indication for PCI aiming at assessing the agreement and accuracy of the HeartFlow Planner with invasive fractional flow reserve (FFR) as a reference.

Read the detailed description

Multicenter study, including 120 patients at 5 centers in Europe and Asia. After identifying the presence of significant coronary stenosis by means of coronary angiography and invasive fractional flow reserve (FFR≤0.80) the patients will undergo the following procedures: Invasive FFR with intravenous adenosine (i.e. pre- and post-PCI). Optical coherence tomography-guided PCI (i.e. pre- and post-procedural imaging). PCI with newer generation drug-eluting stent.

02

Conditions studied

  • Stable Coronary Artery Disease
03

In context

Coronary Artery Disease

4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.

This study's enrollment of 127 is below the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Onze Lieve Vrouw Hospital is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with Stable Coronary Artery Disease with Positive Fractional Flow Reserve and indication for percutaneous myocardial revascularization.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Coronary artery disease in a major epicardial vessel with an invasive fractional flow reserve (FFR) ≤0.80
  • An indication to Percutaneous coronary intervention

Exclusion criteria

Exclusion Criteria:

  • Angiographic exclusion criteria
  1. Severely calcified lesion/vessel
  2. Bifurcation lesions.
  3. Ostial lesions.
  4. Left main disease.
  5. Severe vessel tortuosity.

Clinical exclusion criteria

  1. to adenosine
  2. class III or IV, or last known \<30%
  3. Uncontrolled or recurrent ventricular tachycardia
  4. Atrial fibrillation, flutter or arrhythmia
  5. History of recent stroke (≤90 days)
  6. History of acute coronary syndrome (≤90 days)
  7. Prior myocardial infarction
  8. History of ischemic stroke (>90 days) with modified RANKIN score ≥ 2
  9. History of any hemorrhagic stroke
  10. Previous revascularization (PCI or Coronary artery bypass grafting)
  11. Active liver disease or hepatic dysfunction, defined as or ALT > 3 times the
  12. Severe renal dysfunction, defined as an \<30 mL/min/1.73 m2
  13. >35 kg/m2
  14. Nitrate intolerance
  15. Contra-indication to heart rate lowering drugs

    Imaging-related

  16. Insufficient coronary CT Angiography image quality.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
127 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Single-arm cohort

    Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)

    Diagnostic Test: FFRCT planner

Interventions

  • Diagnostic testFFRCT planner

    Non-invasive post-PCI fractional flow reserve prediction

    Also known as: HeartFlow Planner

06

What researchers measure

Primary outcomes

  1. Agreement on post-PCI fractional flow reserve between virtual treatment based on FFRct planner and measured invasive post-PCI fractional flow reserve.

    The agreement will be assessed by Bland Altman method

    Time frame: The primary endpoint will be assessed immediately after the procedure (PCI).

07

Study locations

1 site
  • OLV-Aalst
    Aalst, Oost-Vlaanderen 9300, Belgium
08

References and documents

Publications

  • Sonck J, Nagumo S, Norgaard BL, Otake H, Ko B, Zhang J, Mizukami T, Maeng M, Andreini D, Takahashi Y, Jensen JM, Ihdayhid A, Heggermont W, Barbato E, Mileva N, Munhoz D, Bartunek J, Updegrove A, Collinsworth A, Penicka M, Van Hoe L, Leipsic J, Koo BK, De Bruyne B, Collet C. Clinical Validation of a Virtual Planner for Coronary Interventions Based on Coronary CT Angiography. JACC Cardiovasc Imaging. 2022 Jul;15(7):1242-1255. doi: 10.1016/j.jcmg.2022.02.003. Epub 2022 Apr 13. PubMed 35798401 ↗

Individual participant data

Plan to share: Undecided — Undecided plan for data sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Dec 2020, 22 months.

Of 634 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 22 months is below that.

Counting every sponsor, half of 759 studies reached it within 40 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2018
First posted
Dec 20, 2018
StartActual
Feb 1, 2019
Primary completionActual
Dec 18, 2020
CompletionActual
Dec 18, 2021
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03782688
Lead sponsor
Onze Lieve Vrouw Hospital
Responsible party
Jeroen Sonck (Co-Director Cardiovascular Center OLV-Aalst, Onze Lieve Vrouw Hospital) — Principal investigator
First posted
Dec 20, 2018
Start date
Feb 1, 2019
Primary completion
Dec 18, 2020
Completion
Dec 18, 2021
Last update
Mar 23, 2023

Study contacts

Bernard De Bruyne, MD, PhD
study chair · OLV-Aalst

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion